ucillia Sericata larval therapy in the treatment of diabetic chronic wounds
Not Applicable
Recruiting
- Conditions
- Diabetic wound.Diabetes mellitus due to underlying condition
- Registration Number
- IRCT20201012049000N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Diabetic patients (more than 15 years old) with chronic wound that signed the informed consent.
Exclusion Criteria
Consumption of drugs that influence the wound healing.
immunosuppress patients like hemophilia and hepatic disease.
scares> 5cm
patients with osteomyelitis, cellulitis and cancers.
patients who needs amputation or flap surgery.
Patients with vascular problems that needs surgery.
Wet and new wounds.
More than one wound.
smoker or burger disease
Claudication or vascular graft problems.
HbA1C>8
ESR, CRP>+1
anticouagulation therapy.
wound under pressure.
fear of insects.
ecxema or skin allergy history.
Chemotherapy or radiotherapy history.
Any sensitivity to special drug.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigation and evaluation of wound size by wound sizing. Timepoint: before intervention and 7 days after. Method of measurement: Evaluation and evaluation of wound size by wound sizing with standard measuring device (strotactic).
- Secondary Outcome Measures
Name Time Method Inflammation and redness or infection at the site of the wound. Timepoint: before intervention and 7 days after. Method of measurement: Medical visit.